Phaseline

Companies › XellSmart Therapeutics (Shanghai)

XellSmart Therapeutics (Shanghai): clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Neurology; next expected readout Jul 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
XS411
human allogeneic iPSC-derived dopaminergic neural progenitor cell injection
–Phase 1Parkinson's DiseaseJul 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07080775XS411Phase 1Parkinson's DiseaseNeurologyJul 2027

Targets

No annotated target.

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.